Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
100%(2 trials)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
2
40%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Active, not recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 32 (40.0%)
N/A1 (20.0%)

Trials by Status

completed240%
withdrawn120%
active_not_recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_3

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444
active_not_recruitingphase_3

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
withdrawnnot_applicable

Mild Cognitive Impairment in Men Following Androgen Deprivation

NCT01691976
completedphase_2

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

NCT01946165
completedphase_2

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529

Clinical Trials (5)

Showing 5 of 5 trials
NCT02446444Phase 3

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Active Not Recruiting
NCT04557059Phase 3

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Active Not Recruiting
NCT01691976Not Applicable

Mild Cognitive Impairment in Men Following Androgen Deprivation

Withdrawn
NCT01946165Phase 2

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Completed
NCT01088529Phase 2

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5